- Home
- IMRX
as 07-11-2025 3:35pm EST
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
| Founded: | 2008 | Country: | United States |
| Employees: | 54 | City: | CAMBRIDGE |
| Market Cap: | 145.7M | IPO Year: | 2021 |
| Target Price: | $13.25 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.96 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.00 - $4.60 | Next Earning Date: | 08-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Immuneering Corporation (IMRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Brakewood Harold Eugene | IMRX | Chief Business Officer | Jun 20 '25 | Buy | $2.53 | 1,900 | $4,804.15 | 5,800 | |
| Hall Brett Matthew | IMRX | CHIEF SCIENTIFIC OFFICER | Jun 20 '25 | Buy | $2.56 | 13,422 | $34,616.17 | 353,311 | |
| Feinberg Peter | IMRX | Director | Jun 18 '25 | Buy | $2.53 | 25,000 | $63,187.50 | 136,766 | |
| Schall Thomas J. | IMRX | Director | Jun 17 '25 | Buy | $2.21 | 40,485 | $89,277.52 | 43,385 |
Latest Immuneering Corporation News
IMRX Breaking Stock News: Dive into IMRX Ticker-Specific Updates for Smart Investing
Argus Research
17 days ago
Daily – Vickers Top Buyers & Sellers for 06/25/2025
Simply Wall St.
22 days ago
We're A Little Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate
MT Newswires
24 days ago
Mizuho Raises Price Target on Immuneering to $10 From $8, Keeps Outperform Rating
GlobeNewswire
25 days ago
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
GlobeNewswire
a month ago
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
GlobeNewswire
a month ago
Immuneering to Present at the Jefferies Global Healthcare Conference
GlobeNewswire
2 months ago
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
3 months ago
Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
Compare IMRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMRX Immuneering Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.